Cost-effectiveness analysis of retlirafusp alfa combined with chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma

Background The phase III RELIGHT trial demonstrated that retlirafusp alfa plus CAPOX (RTL-CHE) significantly improved overall survival versus placebo plus CAPOX (PLA-CHE) as first-line treatment for patients with programmed death-ligand 1 (PD-L1)-positive (combined positive score [CPS] ≥ 1), human epidermal growth factor receptor 2 (HER2)-negative advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. However, the cost-effectiveness of RTL-CHE remains unclear. This study assessed its cost-effectiveness as first-line therapy versus PLA-CHE from the perspective of the Chinese healthcare system. Methods Using data from the RELIGHT trial, a Markov model was developed with a 21-day cycle and a 10-year time horizon. Analyses were conducted from the Chinese healthcare system perspective, with costs and outcomes discounted at 4.5% annually. Outcomes included total costs and quality-adjusted life-years (QALYs). Cost-effectiveness was assessed using the incremental cost-effectiveness ratio (ICER), with a willingness-to-pay (WTP) threshold of $27,906/QALY. One-way and probabilistic sensitivity analyses were performed. Subgroup, scenario, and threshold analyses were also conducted. Subgroup analyses were performed in patients with CPS ≥ 5 and those with CPS ≥ 1 and < 5. Scenario analyses included the intention-to-treat (ITT) population, shorter time horizons, and vial wastage assumptions. Threshold analyses were used to explore price adjustments and determine the cost-effective threshold price. Results In the base-case analysis, RTL-CHE yielded 1.45 QALYs at a total cost of $75,079.76, compared with 0.82 QALYs at a total cost of $11,552.25 for PLA-CHE, resulting in an ICER of $100,837.32 per QALY gained. One-way sensitivity analysis identified retlirafusp alfa cost, body weight, and PFS utility as the most influential parameters. In subgroup analyses, the ICER was $94,856.54 per QALY in patients with CPS ≥ 5 and $126,414.40 per QALY in those with CPS ≥ 1 and < 5. In the scenario analysis of the ITT population, the ICER was $132,323.07 per QALY. The ICERs in the base-case, subgroup, and scenario analyses all exceeded the WTP threshold of $27,906 per QALY. To reach the WTP threshold, the price of retlirafusp alfa would need to fall to $47.41 per 100 mg. Conclusion From the perspective of the Chinese healthcare system, RTL-CHE is not cost-effective as first-line treatment for PD-L1-positive (CPS ≥ 1), HER2-negative advanced G/GEJ adenocarcinoma compared with PLA-CHE.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2026-11-17
DOI
https://doi.org/10.3389/fphar.2026.2033820
Primary Topic
Health Systems, Economic Evaluations, Quality of Life
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Cost-effectiveness analysis of retlirafusp alfa combined with chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma

Danxue Huang, Su Li, Jing Xiang, Na Li
8 links
Frontiers in Pharmacology
Health Systems, Economic Evaluations, Quality of Life
article

Cost-effectiveness analysis of retlirafusp alfa combined with chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma

Danxue Huang, Su Li, Jing Xiang, Na Li
article en

Abstract

Background The phase III RELIGHT trial demonstrated that retlirafusp alfa plus CAPOX (RTL-CHE) significantly improved overall survival versus placebo plus CAPOX (PLA-CHE) as first-line treatment for patients with programmed death-ligand 1 (PD-L1)-positive (combined positive score [CPS] ≥ 1), human epidermal growth factor receptor 2 (HER2)-negative advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. However, the cost-effectiveness of RTL-CHE remains unclear. This study assessed its cost-effectiveness as first-line therapy versus PLA-CHE from the perspective of the Chinese healthcare system. Methods Using data from the RELIGHT trial, a Markov model was developed with a 21-day cycle and a 10-year time horizon. Analyses were conducted from the Chinese healthcare system perspective, with costs and outcomes discounted at 4.5% annually. Outcomes included total costs and quality-adjusted life-years (QALYs). Cost-effectiveness was assessed using the incremental cost-effectiveness ratio (ICER), with a willingness-to-pay (WTP) threshold of $27,906/QALY. One-way and probabilistic sensitivity analyses were performed. Subgroup, scenario, and threshold analyses were also conducted. Subgroup analyses were performed in patients with CPS ≥ 5 and those with CPS ≥ 1 and < 5. Scenario analyses included the intention-to-treat (ITT) population, shorter time horizons, and vial wastage assumptions. Threshold analyses were used to explore price adjustments and determine the cost-effective threshold price. Results In the base-case analysis, RTL-CHE yielded 1.45 QALYs at a total cost of $75,079.76, compared with 0.82 QALYs at a total cost of $11,552.25 for PLA-CHE, resulting in an ICER of $100,837.32 per QALY gained. One-way sensitivity analysis identified retlirafusp alfa cost, body weight, and PFS utility as the most influential parameters. In subgroup analyses, the ICER was $94,856.54 per QALY in patients with CPS ≥ 5 and $126,414.40 per QALY in those with CPS ≥ 1 and < 5. In the scenario analysis of the ITT population, the ICER was $132,323.07 per QALY. The ICERs in the base-case, subgroup, and scenario analyses all exceeded the WTP threshold of $27,906 per QALY. To reach the WTP threshold, the price of retlirafusp alfa would need to fall to $47.41 per 100 mg. Conclusion From the perspective of the Chinese healthcare system, RTL-CHE is not cost-effective as first-line treatment for PD-L1-positive (CPS ≥ 1), HER2-negative advanced G/GEJ adenocarcinoma compared with PLA-CHE.

Frontiers in PharmacologyVol. 17
Liaoning Cancer Hospital & Institute (CN)
Good health and well-being
Health Systems, Economic Evaluations, Quality of Life
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon